When we looked at the association of p53 with the occurrence of skin rash (a well known side-effect of erlotinib and other anti-EGFR drugs and a predictive ‘clinical marker’ for drug efficacy) we found rash - of any grade - in 84% of the patients whose tumor carried a regular p53 expression, whereas only 25% of patients with a p53 loss developed rash during treatment with erlotinib (p = 0.02). This evidence concerns the gene EGFR and Skin rash.